Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.

Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.

Analyst Comments Analyst EPS View Analyst PT Change

Array BioPharma (ARRY) PT Raised to $23 at CowenFebruary 6, 2019 7:56 AM Array BioPharma (ARRY) PT Raised to $29 at StifelFebruary 5, 2019 3:55 PM Array BioPharma (ARRY) PT Raised to $34 at GuggenheimFebruary 5, 2019 11:57 AM Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues BeatFebruary 5, 2019 8:02 AM Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019February 5, 2019 8:00 AM